Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Paediatr Drugs

Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.

Published: November 2022

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592650PMC
http://dx.doi.org/10.1007/s40272-022-00514-1DOI Listing

Publication Analysis

Top Keywords

nsaids infants
16
safety nsaids
12
safety efficacy
12
nsaids
10
children adolescents
8
effects nsaids
8
efficacy nsaids
8
infants data
8
conditions fever
8
adverse drug
8

Similar Publications

Introduction: Anakinra has dramatically improved the management of systemic juvenile idiopathic arthritis (SJIA) over the last decade. Nevertheless, management remains inconsistent; corticosteroids are still frequently used. We analyzed the course of SJIA in children treated with anakinra according to the time of treatment initiation after disease onset.

View Article and Find Full Text PDF
Article Synopsis
  • - The case involves a 2-month-old Iranian boy who developed persistent fever after receiving a 5-in-1 vaccine, leading to a diagnosis of atypical Kawasaki disease, which is rare in infants.
  • - Initial tests showed abnormal blood counts and echoed results revealed giant coronary artery aneurysms, highlighting serious complications related to the disease.
  • - The case stresses the importance of timely diagnosis and treatment for Kawasaki disease in infants, emphasizing healthcare providers' need to recognize it in similar situations to prevent severe health outcomes.
View Article and Find Full Text PDF

Background: Empirically evaluating the potential impact of recall bias on observed associations of prenatal medication exposure is crucial.

Objective: We sought to assess the effects of exposure misclassification on previous studies of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in early pregnancy and increased risk of amniotic band syndrome (ABS).

Methods: Using data from the National Birth Defects Prevention Study (NBDPS) on births from 1997 to 2011, we included 189 mothers of infants with ABS and 11,829 mothers of infants without congenital anomalies.

View Article and Find Full Text PDF

Closure of the ductus arteriosus (DA) using cyclooxygenase (COX) inhibitors is considered the first-line treatment for hemodynamically significant patent ductus arteriosus (PDA). Physiologically, prostaglandins have a recognized role in PDA. Admittedly, the comparative efficacy and safety between ibuprofen and acetaminophen need to be determined for rational choice of drug therapy for closure of the DA in clinical protocols.

View Article and Find Full Text PDF

Background: Acquired spontaneous intestinal perforation or SIP occurs most commonly in the extremely premature infant population. As the incidence is rising, understanding modifiable factors such as common medication exposures becomes important for individualizing care.

Methods: The primary outcome was SIP in premature infants with exposure to indomethacin, ibuprofen, or acetaminophen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!